{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:44:05Z","timestamp":1778906645012,"version":"3.51.4"},"reference-count":24,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,6,18]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Atezolizumab is a humanised monoclonal IgG1 antibody that is used in treating many solid malignancies. Endocrinopathies are known but a rare adverse event of these immunotherapeutic drugs. Autoimmune diabetes induced by atezolizumab has been rarely reported in the literature. We report the case of a woman in her eighth decade with no known history of diabetes who developed new-onset autoimmune diabetes and Takotsubo cardiomyopathy due to the adverse effects of atezolizumab therapy for hepatocellular carcinoma. We also review the characteristics and outcomes of cases previously reported in the literature.<\/jats:p>","DOI":"10.1136\/bcr-2022-250662","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T12:00:44Z","timestamp":1657108844000},"page":"e250662","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy"],"prefix":"10.1136","volume":"15","author":[{"given":"Sachi","family":"Singhal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Crozer-Chester Medical Center, Upland, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goonja","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Crozer-Chester Medical Center, Upland, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-3900","authenticated-orcid":false,"given":"Rohan Bir","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Crozer-Chester Medical Center, Upland, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Avgush","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Crozer-Chester Medical Center, Upland, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Koka","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Crozer-Chester Medical Center, Upland, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2025082801375028000_15.7.e250662.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0618-8"},{"key":"2025082801375028000_15.7.e250662.2","unstructured":"FDA . TECENTRIQ (atezolizumab) injection, 2016. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761034s010lbl.pdf"},{"key":"2025082801375028000_15.7.e250662.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2025082801375028000_15.7.e250662.4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e14571","article-title":"The incidence of occult endocrinopathies in patients with cancer undergoing immunotherapy in community practice","volume":"39","author":"Abdalla","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025082801375028000_15.7.e250662.5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00569","article-title":"Role of the PD-1\/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes","volume":"11","author":"Falcone","year":"2020","journal-title":"Front Endocrinol"},{"key":"2025082801375028000_15.7.e250662.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.06.033"},{"key":"2025082801375028000_15.7.e250662.7","unstructured":"Leiter EH . NOD mice and related strains: origins, husbandry, and biology. NOD Mice Relat Strains Res Appl Diabetes, AIDS, Cancer Other Dis 1998;1."},{"key":"2025082801375028000_15.7.e250662.8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220415","article-title":"Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies","volume":"2017","author":"Way","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2025082801375028000_15.7.e250662.9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-017-0480-y","article-title":"Anti-PD-L1 atezolizumab-Induced autoimmune diabetes: a case report and review of the literature","volume":"12","author":"Hickmott","year":"2017","journal-title":"Target Oncol"},{"key":"2025082801375028000_15.7.e250662.10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","author":"Kapke","year":"2017","journal-title":"Case Rep Oncol"},{"key":"2025082801375028000_15.7.e250662.11","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1097\/MJT.0000000000000644","article-title":"Atezolizumab-Induced new onset diabetes mellitus with ketoacidosis","volume":"25","author":"Patti","year":"2018","journal-title":"Am J Ther"},{"key":"2025082801375028000_15.7.e250662.12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00352","article-title":"Atezolizumab-Induced autoimmune diabetes in a patient with metastatic lung cancer","volume":"10","author":"Sothornwit","year":"2019","journal-title":"Front Endocrinol"},{"key":"2025082801375028000_15.7.e250662.13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025082801375028000_15.7.e250662.14","doi-asserted-by":"crossref","first-page":"e00685","DOI":"10.1002\/rcr2.685","article-title":"Atezolizumab-induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation","volume":"8","author":"Nishioki","year":"2020","journal-title":"Respirol Case Rep"},{"key":"2025082801375028000_15.7.e250662.15","first-page":"e30","article-title":"A unique case of Atezolizumab-Induced autoimmune diabetes","volume":"6","author":"Wong","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"2025082801375028000_15.7.e250662.16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-233842","article-title":"Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma","volume":"13","author":"Rahman","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2025082801375028000_15.7.e250662.17","first-page":"190","article-title":"Atezolizumab-induced autoimmune diabetes in a patient with metastatic breast cancer: a case report","volume":"5","author":"Clontz","year":"2021","journal-title":"Clin Pract Cases Emerg Med"},{"key":"2025082801375028000_15.7.e250662.18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0659"},{"key":"2025082801375028000_15.7.e250662.19","first-page":"76","article-title":"Takotsubo cardiomyopathy, or broken-heart syndrome","volume":"34","author":"Virani","year":"2007","journal-title":"Texas Hear Inst J"},{"key":"2025082801375028000_15.7.e250662.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl032"},{"key":"2025082801375028000_15.7.e250662.21","doi-asserted-by":"publisher","DOI":"10.1177\/2048872615589512"},{"key":"2025082801375028000_15.7.e250662.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406761"},{"key":"2025082801375028000_15.7.e250662.23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.acvd.2015.08.004","article-title":"Management of takotsubo cardiomyopathy in non-academic hospitals in France: the observational French syndromes of takotsubo (OFSETT) study","volume":"109","author":"Yayehd","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"2025082801375028000_15.7.e250662.24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009003","article-title":"Association of endocrine conditions with takotsubo cardiomyopathy: a comprehensive review","volume":"7","author":"Gupta","year":"2018","journal-title":"J Am Heart Assoc"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-250662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:38:02Z","timestamp":1756370282000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-250662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,6]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bcr-2022-250662"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-250662","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}